Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

EG 427’s Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint

Paris, Jan. 06, 2026 (GLOBE NEWSWIRE) -- 88% reduction in urinary incontinence episodes in patients with neurogenic bladder ...